|
|
|
Stem Cell Related Patent Number US6818612
| Title: | Use of parvovirus capsid particles in the inhibition of cell proliferation and migration | | Inventors: | Broliden, Kristina; S-182 39 Danderyd, Sweden
Westgren, Magnus; S-112 20 Stockholm, Sweden | | Summary: | Described herein is a method of inhibiting hematopoiesis. This invention relates to the use of empty non-infectious recombinant B19 parvovirus capsids, B19 capsid proteins or fragments of B19 capsid proteins for the production of a medicament for the inhibition of growth or the migration of cells containing the P antigen. Central to the invention is the discovery of methods and compositions involved in the inhibition of growth and/or the migration of cells that have a receptor that interacts with a parvovirus B19 capsid or fragment thereof, such as a P antigen containing cell, which includes also cells of hematopoietic origin and endothelial cells. Further disclosed are methods by which parvovirus capsid particles or fragments of parvovirus capsid proteins are used to manufacture medicaments that can be administered to a subject to inhibit hematopoietic progenitor cell growth prior to stem cell transplantation. Endothelial cell growth is further inhibited such as in anti-tumorigenesis treatment or to prevent restenosis or fibrotic build up following prosthetic implantation, or to prevent disorders that involve the abnormal proliferation of cells that have the P antigen such as Polycythemia Vera. | | Abstract: | The invention described herein relates to the discovery of methods and compositions for the inhibition of growth and/or migration of cells that have a receptor that interacts with a parvovirus B19 capsid or fragment thereof (e.g., a P antigen containing cell), including but not limited to, cells of hematopoietic origin and endothelial cells. More specifically, parvovirus capsid particles or fragments of parvovirus capsid proteins are used to manufacture medicaments that can be administered to a subject to inhibit hematopoietic progenitor cell growth (e.g., prior to stem cell transplantation), endothelial cell growth, (e.g., as an anti-tumorigenesis treatment or to prevent restenosis or fibrotic build up following prosthetic implantation), or to prevent disorders that involve the abnormal proliferation of cells that have the P antigen (e.g., Polycythemia Vera). | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6818612 | | Application Number: | US2001000991433 | | Date Filed: | 16/11/2001 | | Date Published: | 16/11/2004 | | Assignee: | None |
|
|
